Ascendis Pharma A/S (BVMF:A1SN34)
94.41
0.00 (0.00%)
At close: Nov 6, 2026
Ascendis Pharma Employees
Ascendis Pharma had 1,189 employees as of December 31, 2025. The number of employees increased by 172 or 16.91% compared to the previous year.
Employees
1,189
Change (1Y)
172
Growth (1Y)
16.91%
Revenue / Employee
5.21M BRL
Profits / Employee
3.69M BRL
Market Cap
92.74B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 1,189 | 172 | 16.91% |
| Dec 31, 2024 | 1,017 | 138 | 15.70% |
| Dec 31, 2023 | 879 | 82 | 10.29% |
| Jan 1, 2023 | 797 | 158 | 24.73% |
| Dec 31, 2021 | 639 | 157 | 32.57% |
| Dec 31, 2020 | 482 | 152 | 46.06% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Raia Drogasil | 77,428 |
| Fleury | 29,000 |
| Empreendimentos Pague Menos | 28,534 |
| Diagnósticos da América | 26,255 |
| Dimed S.A. Distribuidora de Medicamentos | 11,426 |
| Hypera | 10,564 |
| Blau Farmacêutica | 1,900 |
| Ouro Fino Saúde Animal Participações | 1,086 |
Ascendis Pharma News
- 3 days ago - Ascendis gets COMP opinion for TransCon CNP orphan designation maintenance - TheFly
- 3 days ago - Once-Weekly TransCon® CNP (Navepegritide) to Receive 10 Years of Market Exclusivity Upon Approval in the European Union - GlobeNewsWire
- 3 days ago - Ascendis to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026 - GlobeNewsWire
- 14 days ago - Ascendis Pharma announces new data from PaTH Forward, PaTHway trials - TheFly
- 14 days ago - TransCon® PTH (Palopegteriparatide) Demonstrates Sustained, Clinically Meaningful Improvements in Kidney Function in Adults with Hypoparathyroidism Treated Up to 5 Years - GlobeNewsWire
- 14 days ago - Ascendis Pharma initiated with a Hold at Canaccord - TheFly
- 14 days ago - Ascendis Pharma price target lowered to $330 from $360 at Citi - TheFly
- 24 days ago - Ascendis gets CHMP opinion recommending marketing authorization for TransCon CNP - TheFly